Drug
Arct 810
Arct 810: highest development phase Phase 2, developed by Arcturus Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Arcturus Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARCT-810 NCT06488313 | Phase 2 | OTC Deficiency |
| ARCT-810 NCT05526066 | Phase 2 | Ornithine Transcarbamylase Deficiency |
| ARCT-810 NCT04416126 | Phase 1 | Ornithine Transcarbamylase Deficiency |
| ARCT-810 NCT04442347 | Phase 1 | Ornithine Transcarbamylase Deficiency |
Latest
No recent events.
Follow Arct 810 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.